<code id='F6FFDCA377'></code><style id='F6FFDCA377'></style>
      • <acronym id='F6FFDCA377'></acronym>
      <center id='F6FFDCA377'><center id='F6FFDCA377'><tfoot id='F6FFDCA377'></tfoot></center><abbr id='F6FFDCA377'><dir id='F6FFDCA377'><tfoot id='F6FFDCA377'></tfoot><noframes id='F6FFDCA377'>
      • <optgroup id='F6FFDCA377'><strike id='F6FFDCA377'><sup id='F6FFDCA377'></sup></strike><code id='F6FFDCA377'></code></optgroup>
        5. <b id='F6FFDCA377'><label id='F6FFDCA377'><select id='F6FFDCA377'><dt id='F6FFDCA377'><span id='F6FFDCA377'></span></dt></select></label></b><u id='F6FFDCA377'></u>
          <i id='F6FFDCA377'><strike id='F6FFDCA377'><tt id='F6FFDCA377'><pre id='F6FFDCA377'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / fashion / knowledge      
           
     
           
      
          knowledge 
           
      
           
      
           
       2025-10-01 18:00:29 
   
      
           
      
           
                        
          knowledge  
          
                                   
                 
                                      author：comprehensive   
                                        
                                      
                                      Page View：94
                                  
                                    
          
                                   
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand.																									Adobe 
          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.
          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.
          advertisement
          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers
                                
                            
          Next article：  
                                      
                                          Medicare proposal to cover medical devices draws a mixed reaction
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles